Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinsonʼs Disease
- 26 September 2019
- journal article
- research article
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 85 (17) , 1351-1362
Abstract
Atremorine is a novel bioproduct with neuroprotective effects on dopaminergic neurons and a natural L-DOPA donor in Parkinsonʼs disease (PD). In the present study, we show the effects of a single dose of Atremorine (5 g, p. o.) on plasma dopamine (DA) response and brain function in PD (n = 183) and the influence that pathogenic (LRRK2), metabolic (CYP2D5, CYP2C9, CYP2C19, CYP3A5, NAT2), transporter (ABCB1), pleiotropic (APOE), and detoxifying genes (CYP1B1, GSTT1, GSTP1, GSTM1, SOD2) involved in the pharmacogenetic network exerts on Atremorine-induced DA response. Over 90% of PD patients at diagnosis show plasma DA levels below 20 pg/mL. Atremorine induces DA synthesis causing a significant increase in plasma DA levels 1 h after administration in practically 100% of patients. Females tend to show lower basal DA levels than males and the response of DA to Atremorine is stronger in males than in females. Atremorine-induced DA response is pharmacogenotype-specific and lasts from 6 – 12 h depending upon the pharmacogenetic profile of each patient. Genetic variants in pathogenic genes, metabolic genes, and genes involved in the detoxification processes affect the response of DA to Atremorine in a genotype-specific manner. Atremorine or any of its bioactive components can cross the blood-brain barrier and improve brain function and motor function, as revealed by the reduction in slow wave activity in brain mapping and psychometric assessment, respectively. Atremorine is a selective neuroprotective agent for dopaminergic neurons with prophylactic and therapeutic potential in PD.Keywords
This publication has 14 references indexed in Scilit:
- TheL-dopa story: Translational neuroscience ante verbumClinical and Translational Neuroscience, 2018
- Time Trends in the Incidence of Parkinson DiseaseJAMA Neurology, 2016
- Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysisJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Polymorphic metabolism by functional alterations of human cytochrome P450 enzymesArchives of Pharmacal Research, 2011
- Levodopa: Past, Present, and FutureEuropean Neurology, 2008
- The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubulesJournal of Neuroscience Research, 2008
- Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degenerationProceedings of the National Academy of Sciences, 2005
- Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European PopulationsThe American Journal of Human Genetics, 2005
- Polymorphic variants of the beta-2-adrenergic receptor (ADRB2) gene and ADRB2-related propranolol-induced dyslipidemia in the Colombian populationMethods and Findings in Experimental and Clinical Pharmacology, 2005
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic PathologyNeuron, 2004